Phase II, Randomised, Placebo-controlled, Double Blind, Parallel Group, Single Centre Study Investigating Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder
Phase: PHASE2 | Sponsor: Psychiatric University Hospital, Zurich | Compound: Ketamine
- Status
- planned
- Institution
- Psychiatric University Hospital, Zurich
- Start date
- 2025-05-01
- End date
- 2026-12-01
- Registry ID
- NCT06969937
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.